Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04939805
Other study ID # 20210121-2475
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2021
Est. completion date March 31, 2025

Study information

Verified date March 2024
Source Medical University Innsbruck
Contact Sebastian J Reinstadler, MD, PhD
Phone +43 (0) 512 504 25665
Email sebastian.reinstadler@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background: In patients with acute ST-elevation myocardial infarction (STEMI), the amount of infarcted myocardium (infarct size) is known to be a major predictor for adverse remodeling and recurrent adverse cardiovascular events. Effective cardio-protective strategies with the aim of reducing infarct size are therefore of great interest. Local and systemic inflammation influences the fate of ischemic myocardium and thus, adverse remodeling and clinical outcome. C-reactive protein (CRP) also acts as a potential mechanistic mediator that adversely affects the amount of irreversible myocardial tissue damage after acute myocardial infarction. Objective: The main objectives of the current study are to investigate the efficacy of selective CRP apheresis, using the PentraSorb®-CRP system, as an adjunctive therapy to standard of care for patients with acute STEMI treated with primary PCI. Design: Investigator-initiated, prospective, randomized, open-label (outcome assessors masked), controlled, multicenter, two group trial with a two-stage adaptive design. Innovation: Selective CRP apheresis offers potential to decrease infarct size and consequently improve outcome after PCI for STEMI. This is the first randomized trial investigating the impact of selective CRP apheresis on infarct size in post-STEMI patients. In perspective, the study design allows furthermore to collect robust evidence for the design of a definitive outcome study.


Recruitment information / eligibility

Status Recruiting
Enrollment 202
Est. completion date March 31, 2025
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. Diagnosis of first acute STEMI in accordance with the European Society of Cardiology (ESC) Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation 2. Symptoms consistent with STEMI with beginning greater than 30 minutes but less than 12 hours prior to primary percutaneous coronary intervention (PCI) 3. CRP elevation of =7 mg/l measured between 6 to 16 hours after primary PCI 4. Eligible for primary PCI 5. Age =18 years 6. Written informed consent Exclusion Criteria: 1. Prior acute myocardial infarction, coronary artery bypass surgery or PCI. 2. Persistent hemodynamic instability (Killip class >2 including cardiogenic shock) or resuscitated cardiac arrest not allowing a CMR scan. 3. The patient is febrile (temperature >38°C) or has experienced an acute infection with fever in the last 14 days. 4. CRP >15 mg/l at time of hospital admission. 5. Chronic inflammatory disease. 6. Known history of severe hepatic failure 7. Chronic kidney disease with a creatinine clearance <30ml/min./1.73m² 8. Contraindication to CMR. 9. Pre-STEMI life expectancy of <1 year 10. Participation in another interventional trial 11. Limited possibility to join the follow-up examinations (e.g. patient lives abroad) 12. Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Selective CRP apheresis using the PentraSorb®-CRP system
Selective CRP apheresis as an adjunct to standard of care. Apheresis using the PentraSorb®-CRP system will be performed at day 1, 2 and 3 after PCI.

Locations

Country Name City State
Austria University Clinic for Cardiology and Nephrology, Medical University of Graz Graz
Austria University Clinic of Internal Medicine III, Cardiology and Angiology. University Clinic of Internal Medicine IV, Nephrology and Hypertensiology. University Clinic of Radiology. Innsbruck
Austria University Clinic of Internal Medicine II, Paracelsus Medical University Salzburg Salzburg
Germany Leipzig Heart Center Leipzig
Germany Medical Clinic II - University Heart Center Lübeck Lübeck Schleswig-Holstein

Sponsors (1)

Lead Sponsor Collaborator
Medical University Innsbruck

Countries where clinical trial is conducted

Austria,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Primary efficacy endpoint Infarct size expressed as % of left ventricular myocardial mass (LVMM) as visualized by cardiac magnetic resonance (CMR) imaging at 5 ± 2 days post PCI 5 ± 2 days post PCI
Secondary Safety endpoint Adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) during hospitalization for the index event during hospitalization for the index event
Secondary All-cause mortality or hospitalization for heart failure within 12 months after randomization All-cause mortality or hospitalization for heart failure within 12 months after randomization (endpoint of interest with respect to the two-stage adaptive design) within 12 months after randomization
Secondary CMR endpoints defined as: Left ventricular ejection fraction and microvascular obstruction and exploratory (intramyocardial hemorrhage, edema extent, myocardial salvage, native T1 mapping, strain) CMR endpoints will be assessed at baseline, 4 and 12 months CMR follow-up study and are defined according to the Journal of American College of Cardiology Scientific Expert Consensus document. at baseline, 4 months and 12 months after PCI for STEMI
Secondary Hospitalization for heart failure within 12 months after randomization within 12 months after randomization
Secondary Cardiovascular mortality at 12 months within 12 months after randomization
Secondary CRP concentrations CRP concentrations during index hospitalization during hospitalization for the index event
Secondary Left ventricular thrombus formation 5 ± 2 days, 4 months, 12 months post PCI
Secondary Biomarker concentrations of myocardial necrosis (enzymatic infarct size; high-sensitivity troponin T) at baseline, 4 months, 12 months post PCI
Secondary Biomarker concentrations of hemodynamic stress (N-terminal pro-B-Type Natriuretic Peptide) at baseline, 4 months, 12 months post PCI
Secondary Renal function (eGFR) as measured by the MDRD and CKD-EPI formula during hospitalization for the index event
Secondary Renal function (Cystatin C-based calculation of creatinine clearance) during hospitalization for the index event
Secondary Cardiac autonomic function: Deceleration capacity of heart rate 5 ± 2 days, 4 months, 12 months post PCI
Secondary Cardiac autonomic function: Heart rate variability 5 ± 2 days, 4 months, 12 months post PCI
Secondary Cardiac autonomic function: Periodic repolarization dynamics 5 ± 2 days, 4 months, 12 months post PCI
Secondary Cardiac autonomic function: Baroreflex sensitivity 5 ± 2 days, 4 months, 12 months post PCI
Secondary Cardiac autonomic function: Skin sympathetic nerve activity 5 ± 2 days, 4 months, 12 months post PCI
See also
  Status Clinical Trial Phase
Recruiting NCT05601999 - Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction Phase 3
Recruiting NCT06147986 - Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients Phase 2
Not yet recruiting NCT05881382 - Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction Phase 3
Enrolling by invitation NCT02615015 - SNPs in the DNase 1 Gene Impair Its Activity and Are Increased in a STE-ACS Patient Cohort Compared to Healthy Controls N/A
Recruiting NCT05812963 - IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute STEMI N/A
Recruiting NCT05554588 - Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI N/A
Recruiting NCT05450757 - Shanghai ST-segment Elevation Myocardial Infarction Cohort
Active, not recruiting NCT03278509 - Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART) Phase 4
Not yet recruiting NCT03266328 - Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University N/A
Completed NCT03156699 - The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction
Not yet recruiting NCT03263468 - Revascularization StrategIes for ST Elevation Myocardial Infarction Trial N/A
Enrolling by invitation NCT04970238 - Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction Phase 4
Recruiting NCT02557217 - NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction Phase 2
Recruiting NCT02224534 - Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction Phase 4
Completed NCT01136187 - Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (PCI) N/A
Not yet recruiting NCT04068116 - Impact of Ischemic Post-conditioning N/A
Not yet recruiting NCT04063345 - Long-term Clinical Outcomes of intraVascular Ultrasound-guided vs Angiography-guided Primary pErcutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction Phase 2/Phase 3
Active, not recruiting NCT03646357 - BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function Phase 4
Completed NCT03984071 - The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI
Completed NCT03740776 - The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI